nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—Methylprednisolone—multiple sclerosis	0.0692	0.232	CbGbCtD
Dabigatran etexilate—ABCB1—Mitoxantrone—multiple sclerosis	0.0505	0.169	CbGbCtD
Dabigatran etexilate—ABCB1—Betamethasone—multiple sclerosis	0.045	0.151	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisolone—multiple sclerosis	0.0444	0.149	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisone—multiple sclerosis	0.0419	0.141	CbGbCtD
Dabigatran etexilate—ABCB1—Dexamethasone—multiple sclerosis	0.0262	0.0878	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—multiple sclerosis	0.021	0.0705	CbGbCtD
Dabigatran etexilate—F2—leg—multiple sclerosis	0.0187	0.226	CbGeAlD
Dabigatran etexilate—CES2—retina—multiple sclerosis	0.00468	0.0568	CbGeAlD
Dabigatran etexilate—NQO2—brainstem—multiple sclerosis	0.00434	0.0526	CbGeAlD
Dabigatran etexilate—CES2—medulla oblongata—multiple sclerosis	0.00338	0.041	CbGeAlD
Dabigatran etexilate—CES2—midbrain—multiple sclerosis	0.00309	0.0375	CbGeAlD
Dabigatran etexilate—NQO2—medulla oblongata—multiple sclerosis	0.00302	0.0367	CbGeAlD
Dabigatran etexilate—CES2—spinal cord—multiple sclerosis	0.00302	0.0366	CbGeAlD
Dabigatran etexilate—NQO2—midbrain—multiple sclerosis	0.00276	0.0335	CbGeAlD
Dabigatran etexilate—F2—spinal cord—multiple sclerosis	0.00271	0.0328	CbGeAlD
Dabigatran etexilate—NQO2—spinal cord—multiple sclerosis	0.0027	0.0327	CbGeAlD
Dabigatran etexilate—CES2—nervous system—multiple sclerosis	0.00254	0.0308	CbGeAlD
Dabigatran etexilate—CES2—central nervous system—multiple sclerosis	0.00245	0.0297	CbGeAlD
Dabigatran etexilate—CES2—cerebellum—multiple sclerosis	0.00239	0.029	CbGeAlD
Dabigatran etexilate—F2—nervous system—multiple sclerosis	0.00228	0.0276	CbGeAlD
Dabigatran etexilate—NQO2—nervous system—multiple sclerosis	0.00227	0.0275	CbGeAlD
Dabigatran etexilate—F2—central nervous system—multiple sclerosis	0.0022	0.0266	CbGeAlD
Dabigatran etexilate—NQO2—central nervous system—multiple sclerosis	0.00219	0.0265	CbGeAlD
Dabigatran etexilate—NQO2—cerebellum—multiple sclerosis	0.00214	0.0259	CbGeAlD
Dabigatran etexilate—CES1—nervous system—multiple sclerosis	0.00209	0.0254	CbGeAlD
Dabigatran etexilate—CES1—central nervous system—multiple sclerosis	0.00202	0.0244	CbGeAlD
Dabigatran etexilate—CES2—brain—multiple sclerosis	0.00194	0.0236	CbGeAlD
Dabigatran etexilate—F2—brain—multiple sclerosis	0.00174	0.0211	CbGeAlD
Dabigatran etexilate—NQO2—brain—multiple sclerosis	0.00174	0.0211	CbGeAlD
Dabigatran etexilate—CES1—brain—multiple sclerosis	0.0016	0.0194	CbGeAlD
Dabigatran etexilate—ABCB1—retina—multiple sclerosis	0.000903	0.0109	CbGeAlD
Dabigatran etexilate—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000693	0.00326	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—ALB—multiple sclerosis	0.000683	0.00321	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ICAM1—multiple sclerosis	0.000666	0.00313	CbGpPWpGaD
Dabigatran etexilate—ABCB1—medulla oblongata—multiple sclerosis	0.000653	0.00791	CbGeAlD
Dabigatran etexilate—UGT2B15—Metabolism—SRM—multiple sclerosis	0.000626	0.00294	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IFNG—multiple sclerosis	0.000623	0.00293	CbGpPWpGaD
Dabigatran etexilate—F2—Thrombin signalling through proteinase activated receptors (PARs)—MAPK1—multiple sclerosis	0.000615	0.00289	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000602	0.00148	CcSEcCtD
Dabigatran etexilate—Dizziness—Cladribine—multiple sclerosis	0.000599	0.00147	CcSEcCtD
Dabigatran etexilate—ABCB1—midbrain—multiple sclerosis	0.000596	0.00723	CbGeAlD
Dabigatran etexilate—F2—Folate Metabolism—CCL2—multiple sclerosis	0.000596	0.0028	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000595	0.00147	CcSEcCtD
Dabigatran etexilate—Infection—Mitoxantrone—multiple sclerosis	0.000592	0.00146	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000591	0.00278	CbGpPWpGaD
Dabigatran etexilate—Shock—Mitoxantrone—multiple sclerosis	0.000586	0.00144	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000586	0.00144	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000583	0.00143	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Azathioprine—multiple sclerosis	0.000582	0.00143	CcSEcCtD
Dabigatran etexilate—ABCB1—spinal cord—multiple sclerosis	0.000582	0.00706	CbGeAlD
Dabigatran etexilate—UGT2B15—Biological oxidations—POMC—multiple sclerosis	0.00058	0.00272	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Mitoxantrone—multiple sclerosis	0.000578	0.00142	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Betamethasone—multiple sclerosis	0.000577	0.00142	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Dexamethasone—multiple sclerosis	0.000577	0.00142	CcSEcCtD
Dabigatran etexilate—Vomiting—Cladribine—multiple sclerosis	0.000576	0.00142	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.000574	0.0027	CbGpPWpGaD
Dabigatran etexilate—Haemorrhage—Betamethasone—multiple sclerosis	0.000574	0.00141	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Dexamethasone—multiple sclerosis	0.000574	0.00141	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methylprednisolone—multiple sclerosis	0.000572	0.00141	CcSEcCtD
Dabigatran etexilate—Rash—Cladribine—multiple sclerosis	0.000571	0.00141	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cladribine—multiple sclerosis	0.000571	0.0014	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00057	0.0014	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000569	0.0014	CcSEcCtD
Dabigatran etexilate—Headache—Cladribine—multiple sclerosis	0.000568	0.0014	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000565	0.00265	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000565	0.00265	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—multiple sclerosis	0.000562	0.00264	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—S1PR1—multiple sclerosis	0.000558	0.00262	CbGpPWpGaD
Dabigatran etexilate—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000557	0.00137	CcSEcCtD
Dabigatran etexilate—Hypotension—Mitoxantrone—multiple sclerosis	0.000556	0.00137	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL1B—multiple sclerosis	0.000556	0.00261	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ALB—multiple sclerosis	0.000555	0.00261	CbGpPWpGaD
Dabigatran etexilate—Malnutrition—Methylprednisolone—multiple sclerosis	0.000549	0.00135	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000549	0.00135	CcSEcCtD
Dabigatran etexilate—Angioedema—Prednisolone—multiple sclerosis	0.000547	0.00135	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Prednisone—multiple sclerosis	0.000546	0.00134	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Azathioprine—multiple sclerosis	0.000543	0.00134	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000543	0.00133	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00054	0.00254	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00054	0.00254	CbGpPWpGaD
Dabigatran etexilate—Nausea—Cladribine—multiple sclerosis	0.000538	0.00132	CcSEcCtD
Dabigatran etexilate—Syncope—Prednisolone—multiple sclerosis	0.000537	0.00132	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.000534	0.00251	CbGpPWpGaD
Dabigatran etexilate—Back pain—Triamcinolone—multiple sclerosis	0.000532	0.00131	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000531	0.00131	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000529	0.00249	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—multiple sclerosis	0.000528	0.00248	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Prednisolone—multiple sclerosis	0.000526	0.00129	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000524	0.00129	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000524	0.00246	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Dexamethasone—multiple sclerosis	0.000521	0.00128	CcSEcCtD
Dabigatran etexilate—Angiopathy—Betamethasone—multiple sclerosis	0.000521	0.00128	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.000519	0.00244	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Prednisolone—multiple sclerosis	0.000517	0.00127	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000514	0.00242	CbGpPWpGaD
Dabigatran etexilate—Fatigue—Mitoxantrone—multiple sclerosis	0.000513	0.00126	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB1—multiple sclerosis	0.000513	0.00241	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000513	0.00241	CbGpPWpGaD
Dabigatran etexilate—Constipation—Mitoxantrone—multiple sclerosis	0.000509	0.00125	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IFNG—multiple sclerosis	0.000507	0.00238	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Azathioprine—multiple sclerosis	0.000504	0.00124	CcSEcCtD
Dabigatran etexilate—Angioedema—Triamcinolone—multiple sclerosis	0.000503	0.00124	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Prednisone—multiple sclerosis	0.000502	0.00124	CcSEcCtD
Dabigatran etexilate—Angioedema—Methylprednisolone—multiple sclerosis	0.000502	0.00123	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—multiple sclerosis	0.0005	0.00123	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Prednisone—multiple sclerosis	0.0005	0.00123	CcSEcCtD
Dabigatran etexilate—Syncope—Triamcinolone—multiple sclerosis	0.000494	0.00121	CcSEcCtD
Dabigatran etexilate—Syncope—Methylprednisolone—multiple sclerosis	0.000493	0.00121	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Prednisone—multiple sclerosis	0.000491	0.00121	CcSEcCtD
Dabigatran etexilate—ABCB1—nervous system—multiple sclerosis	0.00049	0.00595	CbGeAlD
Dabigatran etexilate—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000489	0.0012	CcSEcCtD
Dabigatran etexilate—Dizziness—Azathioprine—multiple sclerosis	0.000487	0.0012	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000487	0.0012	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000485	0.00228	CbGpPWpGaD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000485	0.00119	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000484	0.00119	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000483	0.00119	CcSEcCtD
Dabigatran etexilate—Shock—Prednisolone—multiple sclerosis	0.000481	0.00118	CcSEcCtD
Dabigatran etexilate—Cough—Triamcinolone—multiple sclerosis	0.00048	0.00118	CcSEcCtD
Dabigatran etexilate—Hypertension—Triamcinolone—multiple sclerosis	0.000475	0.00117	CcSEcCtD
Dabigatran etexilate—Hypertension—Methylprednisolone—multiple sclerosis	0.000474	0.00117	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000474	0.00222	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Mitoxantrone—multiple sclerosis	0.000473	0.00116	CcSEcCtD
Dabigatran etexilate—ABCB1—central nervous system—multiple sclerosis	0.000472	0.00572	CbGeAlD
Dabigatran etexilate—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000471	0.00116	CcSEcCtD
Dabigatran etexilate—Vomiting—Azathioprine—multiple sclerosis	0.000468	0.00115	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—multiple sclerosis	0.000468	0.00115	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methylprednisolone—multiple sclerosis	0.000468	0.00115	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—multiple sclerosis	0.000465	0.00114	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—multiple sclerosis	0.000465	0.00114	CcSEcCtD
Dabigatran etexilate—Rash—Azathioprine—multiple sclerosis	0.000464	0.00114	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000464	0.00114	CcSEcCtD
Dabigatran etexilate—Dermatitis—Azathioprine—multiple sclerosis	0.000464	0.00114	CcSEcCtD
Dabigatran etexilate—Headache—Azathioprine—multiple sclerosis	0.000461	0.00114	CcSEcCtD
Dabigatran etexilate—ABCB1—cerebellum—multiple sclerosis	0.000461	0.00559	CbGeAlD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000457	0.00215	CbGpPWpGaD
Dabigatran etexilate—Angioedema—Dexamethasone—multiple sclerosis	0.000456	0.00112	CcSEcCtD
Dabigatran etexilate—Angioedema—Betamethasone—multiple sclerosis	0.000456	0.00112	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000456	0.00214	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Prednisone—multiple sclerosis	0.000453	0.00112	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL1B—multiple sclerosis	0.000452	0.00212	CbGpPWpGaD
Dabigatran etexilate—Immune system disorder—Prednisone—multiple sclerosis	0.000451	0.00111	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL2—multiple sclerosis	0.00045	0.00212	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—GPR65—multiple sclerosis	0.00045	0.00211	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000449	0.00111	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000448	0.0011	CcSEcCtD
Dabigatran etexilate—Syncope—Dexamethasone—multiple sclerosis	0.000448	0.0011	CcSEcCtD
Dabigatran etexilate—Syncope—Betamethasone—multiple sclerosis	0.000448	0.0011	CcSEcCtD
Dabigatran etexilate—Infection—Triamcinolone—multiple sclerosis	0.000446	0.0011	CcSEcCtD
Dabigatran etexilate—Infection—Methylprednisolone—multiple sclerosis	0.000445	0.0011	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—multiple sclerosis	0.000444	0.00109	CcSEcCtD
Dabigatran etexilate—Shock—Triamcinolone—multiple sclerosis	0.000442	0.00109	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000441	0.00207	CbGpPWpGaD
Dabigatran etexilate—Shock—Methylprednisolone—multiple sclerosis	0.000441	0.00109	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CYP24A1—multiple sclerosis	0.000441	0.00207	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP27B1—multiple sclerosis	0.000441	0.00207	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.00044	0.00207	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00044	0.00108	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00044	0.00108	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000439	0.00108	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Betamethasone—multiple sclerosis	0.000439	0.00108	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—multiple sclerosis	0.000439	0.00108	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000439	0.00108	CcSEcCtD
Dabigatran etexilate—Nausea—Azathioprine—multiple sclerosis	0.000438	0.00108	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methylprednisolone—multiple sclerosis	0.000435	0.00107	CcSEcCtD
Dabigatran etexilate—Malnutrition—Prednisone—multiple sclerosis	0.000435	0.00107	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—PLEK—multiple sclerosis	0.000433	0.00203	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.000431	0.00203	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Betamethasone—multiple sclerosis	0.000431	0.00106	CcSEcCtD
Dabigatran etexilate—Hypertension—Dexamethasone—multiple sclerosis	0.000431	0.00106	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—MAPK1—multiple sclerosis	0.00043	0.00202	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Mitoxantrone—multiple sclerosis	0.000427	0.00105	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—multiple sclerosis	0.00042	0.00103	CcSEcCtD
Dabigatran etexilate—Hypotension—Methylprednisolone—multiple sclerosis	0.000419	0.00103	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—multiple sclerosis	0.000418	0.00103	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000412	0.00101	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—CCR1—multiple sclerosis	0.000412	0.00193	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL13—multiple sclerosis	0.000412	0.00193	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—multiple sclerosis	0.00041	0.00192	CbGpPWpGaD
Dabigatran etexilate—Urethral disorder—Methotrexate—multiple sclerosis	0.000409	0.00101	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000409	0.00101	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000408	0.001	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000408	0.001	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000408	0.001	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000407	0.001	CcSEcCtD
Dabigatran etexilate—Infection—Dexamethasone—multiple sclerosis	0.000405	0.000996	CcSEcCtD
Dabigatran etexilate—Infection—Betamethasone—multiple sclerosis	0.000405	0.000996	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—multiple sclerosis	0.000403	0.00189	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GPC5—multiple sclerosis	0.000403	0.00189	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000403	0.00189	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Prednisone—multiple sclerosis	0.000402	0.000989	CcSEcCtD
Dabigatran etexilate—Shock—Betamethasone—multiple sclerosis	0.000401	0.000987	CcSEcCtD
Dabigatran etexilate—Shock—Dexamethasone—multiple sclerosis	0.000401	0.000987	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Triamcinolone—multiple sclerosis	0.000401	0.000986	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Dexamethasone—multiple sclerosis	0.0004	0.000984	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Betamethasone—multiple sclerosis	0.0004	0.000984	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000399	0.000982	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000399	0.000982	CcSEcCtD
Dabigatran etexilate—Angioedema—Prednisone—multiple sclerosis	0.000397	0.000978	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Triamcinolone—multiple sclerosis	0.000395	0.000973	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000395	0.000971	CcSEcCtD
Dabigatran etexilate—Syncope—Prednisone—multiple sclerosis	0.00039	0.00096	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisolone—multiple sclerosis	0.000388	0.000955	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—multiple sclerosis	0.000388	0.000954	CcSEcCtD
Dabigatran etexilate—Fatigue—Triamcinolone—multiple sclerosis	0.000387	0.000953	CcSEcCtD
Dabigatran etexilate—Fatigue—Methylprednisolone—multiple sclerosis	0.000386	0.000951	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000385	0.00181	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Prednisone—multiple sclerosis	0.000382	0.000941	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000382	0.00179	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Dexamethasone—multiple sclerosis	0.000381	0.000937	CcSEcCtD
Dabigatran etexilate—Hypotension—Betamethasone—multiple sclerosis	0.000381	0.000937	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—multiple sclerosis	0.000379	0.000932	CcSEcCtD
Dabigatran etexilate—Vomiting—Mitoxantrone—multiple sclerosis	0.000379	0.000932	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—multiple sclerosis	0.000377	0.000928	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000376	0.000926	CcSEcCtD
Dabigatran etexilate—Hypertension—Prednisone—multiple sclerosis	0.000376	0.000924	CcSEcCtD
Dabigatran etexilate—Rash—Mitoxantrone—multiple sclerosis	0.000375	0.000924	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mitoxantrone—multiple sclerosis	0.000375	0.000923	CcSEcCtD
Dabigatran etexilate—ABCB1—brain—multiple sclerosis	0.000375	0.00454	CbGeAlD
Dabigatran etexilate—Headache—Mitoxantrone—multiple sclerosis	0.000373	0.000918	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000371	0.000914	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000371	0.000914	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000371	0.00174	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000371	0.00174	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000371	0.00174	CbGpPWpGaD
Dabigatran etexilate—Arthralgia—Prednisone—multiple sclerosis	0.00037	0.000911	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000368	0.000905	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000367	0.000902	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000366	0.00172	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000366	0.00172	CbGpPWpGaD
Dabigatran etexilate—Malnutrition—Methotrexate—multiple sclerosis	0.000364	0.000894	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisolone—multiple sclerosis	0.00036	0.000886	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.000359	0.00169	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Betamethasone—multiple sclerosis	0.000359	0.000883	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Dexamethasone—multiple sclerosis	0.000359	0.000883	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000358	0.00168	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Triamcinolone—multiple sclerosis	0.000357	0.000878	CcSEcCtD
Dabigatran etexilate—Urticaria—Methylprednisolone—multiple sclerosis	0.000356	0.000876	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000355	0.00167	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Prednisone—multiple sclerosis	0.000355	0.000873	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000355	0.00167	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000354	0.000872	CcSEcCtD
Dabigatran etexilate—Nausea—Mitoxantrone—multiple sclerosis	0.000354	0.00087	CcSEcCtD
Dabigatran etexilate—Infection—Prednisone—multiple sclerosis	0.000353	0.000868	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000352	0.00165	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000352	0.000866	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000352	0.000866	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—multiple sclerosis	0.000352	0.000865	CcSEcCtD
Dabigatran etexilate—Fatigue—Betamethasone—multiple sclerosis	0.000351	0.000865	CcSEcCtD
Dabigatran etexilate—Fatigue—Dexamethasone—multiple sclerosis	0.000351	0.000865	CcSEcCtD
Dabigatran etexilate—Shock—Prednisone—multiple sclerosis	0.000349	0.000859	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000348	0.00164	CbGpPWpGaD
Dabigatran etexilate—Nervous system disorder—Prednisone—multiple sclerosis	0.000348	0.000857	CcSEcCtD
Dabigatran etexilate—Skin disorder—Prednisone—multiple sclerosis	0.000345	0.000848	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—SLC30A7—multiple sclerosis	0.00034	0.0016	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000339	0.00159	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Methotrexate—multiple sclerosis	0.000336	0.000827	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000335	0.00157	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—RRM1—multiple sclerosis	0.000334	0.00157	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000334	0.00157	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000333	0.00082	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000333	0.00082	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000332	0.00156	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000331	0.000814	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00033	0.000813	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TNF—multiple sclerosis	0.000328	0.00154	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—multiple sclerosis	0.000325	0.00153	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Betamethasone—multiple sclerosis	0.000324	0.000797	CcSEcCtD
Dabigatran etexilate—Urticaria—Dexamethasone—multiple sclerosis	0.000324	0.000797	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000323	0.000796	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisolone—multiple sclerosis	0.000323	0.000795	CcSEcCtD
Dabigatran etexilate—Asthenia—Triamcinolone—multiple sclerosis	0.000322	0.000793	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dexamethasone—multiple sclerosis	0.000322	0.000793	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Betamethasone—multiple sclerosis	0.000322	0.000793	CcSEcCtD
Dabigatran etexilate—Asthenia—Methylprednisolone—multiple sclerosis	0.000322	0.000791	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000321	0.00151	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Triamcinolone—multiple sclerosis	0.000318	0.000782	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—multiple sclerosis	0.000317	0.000781	CcSEcCtD
Dabigatran etexilate—Pruritus—Methylprednisolone—multiple sclerosis	0.000317	0.00078	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000315	0.00148	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Prednisone—multiple sclerosis	0.000312	0.000769	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—multiple sclerosis	0.000309	0.000761	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—multiple sclerosis	0.000309	0.000761	CcSEcCtD
Dabigatran etexilate—Rash—Prednisolone—multiple sclerosis	0.000308	0.000758	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisolone—multiple sclerosis	0.000308	0.000757	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000307	0.000756	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000307	0.000755	CcSEcCtD
Dabigatran etexilate—Fatigue—Prednisone—multiple sclerosis	0.000306	0.000753	CcSEcCtD
Dabigatran etexilate—Headache—Prednisolone—multiple sclerosis	0.000306	0.000753	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000305	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SELE—multiple sclerosis	0.000305	0.00143	CbGpPWpGaD
Dabigatran etexilate—Constipation—Prednisone—multiple sclerosis	0.000304	0.000747	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB1—multiple sclerosis	0.000302	0.00142	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Triamcinolone—multiple sclerosis	0.000297	0.000731	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000297	0.00073	CcSEcCtD
Dabigatran etexilate—Dizziness—Methylprednisolone—multiple sclerosis	0.000296	0.000729	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—multiple sclerosis	0.000295	0.000725	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000294	0.00138	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL3—multiple sclerosis	0.000293	0.00138	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Dexamethasone—multiple sclerosis	0.000292	0.00072	CcSEcCtD
Dabigatran etexilate—Asthenia—Betamethasone—multiple sclerosis	0.000292	0.00072	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	0.000292	0.00137	CbGpPWpGaD
Dabigatran etexilate—Nervous system disorder—Methotrexate—multiple sclerosis	0.000291	0.000716	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00029	0.000715	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00029	0.000714	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisolone—multiple sclerosis	0.00029	0.000714	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000289	0.00136	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Dexamethasone—multiple sclerosis	0.000288	0.00071	CcSEcCtD
Dabigatran etexilate—Pruritus—Betamethasone—multiple sclerosis	0.000288	0.00071	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—multiple sclerosis	0.000288	0.000709	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—S1PR1—multiple sclerosis	0.000286	0.00135	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Triamcinolone—multiple sclerosis	0.000286	0.000703	CcSEcCtD
Dabigatran etexilate—Vomiting—Methylprednisolone—multiple sclerosis	0.000285	0.000701	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—SRM—multiple sclerosis	0.000285	0.00134	CbGpPWpGaD
Dabigatran etexilate—Rash—Triamcinolone—multiple sclerosis	0.000283	0.000697	CcSEcCtD
Dabigatran etexilate—Dermatitis—Triamcinolone—multiple sclerosis	0.000283	0.000696	CcSEcCtD
Dabigatran etexilate—Rash—Methylprednisolone—multiple sclerosis	0.000283	0.000695	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methylprednisolone—multiple sclerosis	0.000282	0.000695	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—PTGER4—multiple sclerosis	0.000282	0.00133	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Prednisone—multiple sclerosis	0.000282	0.000694	CcSEcCtD
Dabigatran etexilate—Headache—Triamcinolone—multiple sclerosis	0.000281	0.000693	CcSEcCtD
Dabigatran etexilate—Headache—Methylprednisolone—multiple sclerosis	0.000281	0.000691	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Prednisone—multiple sclerosis	0.000281	0.000691	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Betamethasone—multiple sclerosis	0.000279	0.000686	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dexamethasone—multiple sclerosis	0.000279	0.000686	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—multiple sclerosis	0.000277	0.000682	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—PABPC1—multiple sclerosis	0.000275	0.00129	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000275	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCR3—multiple sclerosis	0.000273	0.00128	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.00027	0.000665	CcSEcCtD
Dabigatran etexilate—Dizziness—Betamethasone—multiple sclerosis	0.00027	0.000663	CcSEcCtD
Dabigatran etexilate—Dizziness—Dexamethasone—multiple sclerosis	0.00027	0.000663	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—RGS1—multiple sclerosis	0.000268	0.00126	CbGpPWpGaD
Dabigatran etexilate—Nausea—Triamcinolone—multiple sclerosis	0.000267	0.000657	CcSEcCtD
Dabigatran etexilate—Nausea—Methylprednisolone—multiple sclerosis	0.000266	0.000655	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—CCR2—multiple sclerosis	0.000265	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL6—multiple sclerosis	0.000265	0.00124	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000265	0.00124	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Methotrexate—multiple sclerosis	0.000264	0.000651	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—POMC—multiple sclerosis	0.000264	0.00124	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Prednisone—multiple sclerosis	0.000262	0.000644	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000261	0.00123	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Methotrexate—multiple sclerosis	0.000261	0.000643	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—multiple sclerosis	0.000261	0.00122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.00026	0.00122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.00026	0.00122	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Dexamethasone—multiple sclerosis	0.000259	0.000638	CcSEcCtD
Dabigatran etexilate—Vomiting—Betamethasone—multiple sclerosis	0.000259	0.000638	CcSEcCtD
Dabigatran etexilate—Rash—Dexamethasone—multiple sclerosis	0.000257	0.000632	CcSEcCtD
Dabigatran etexilate—Rash—Betamethasone—multiple sclerosis	0.000257	0.000632	CcSEcCtD
Dabigatran etexilate—Dermatitis—Dexamethasone—multiple sclerosis	0.000257	0.000632	CcSEcCtD
Dabigatran etexilate—Dermatitis—Betamethasone—multiple sclerosis	0.000257	0.000632	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000256	0.00063	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000256	0.0012	CbGpPWpGaD
Dabigatran etexilate—Fatigue—Methotrexate—multiple sclerosis	0.000256	0.000629	CcSEcCtD
Dabigatran etexilate—Headache—Betamethasone—multiple sclerosis	0.000255	0.000628	CcSEcCtD
Dabigatran etexilate—Headache—Dexamethasone—multiple sclerosis	0.000255	0.000628	CcSEcCtD
Dabigatran etexilate—Asthenia—Prednisone—multiple sclerosis	0.000255	0.000627	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—GPR65—multiple sclerosis	0.000254	0.00119	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000252	0.00119	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Prednisone—multiple sclerosis	0.000251	0.000618	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000249	0.00117	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—RPL5—multiple sclerosis	0.000248	0.00117	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000247	0.00116	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CNR1—multiple sclerosis	0.000245	0.00115	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RGS1—multiple sclerosis	0.000244	0.00114	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Prednisone—multiple sclerosis	0.000243	0.000598	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000243	0.000597	CcSEcCtD
Dabigatran etexilate—Nausea—Betamethasone—multiple sclerosis	0.000242	0.000596	CcSEcCtD
Dabigatran etexilate—Nausea—Dexamethasone—multiple sclerosis	0.000242	0.000596	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—multiple sclerosis	0.000236	0.00058	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisone—multiple sclerosis	0.000235	0.000578	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—multiple sclerosis	0.000235	0.000577	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000233	0.00109	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000233	0.00109	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000233	0.00109	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SRM—multiple sclerosis	0.000232	0.00109	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.000231	0.00109	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GPR65—multiple sclerosis	0.000231	0.00108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.000229	0.00107	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Prednisone—multiple sclerosis	0.000226	0.000555	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000224	0.00105	CbGpPWpGaD
Dabigatran etexilate—Rash—Prednisone—multiple sclerosis	0.000224	0.000551	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisone—multiple sclerosis	0.000224	0.00055	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—LINGO1—multiple sclerosis	0.000223	0.00105	CbGpPWpGaD
Dabigatran etexilate—Headache—Prednisone—multiple sclerosis	0.000222	0.000547	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—ITGA4—multiple sclerosis	0.00022	0.00104	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL10—multiple sclerosis	0.00022	0.00104	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNB1—multiple sclerosis	0.000219	0.00103	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Methotrexate—multiple sclerosis	0.000219	0.000538	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—POMC—multiple sclerosis	0.000215	0.00101	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methotrexate—multiple sclerosis	0.000213	0.000524	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	0.000211	0.000992	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR1—multiple sclerosis	0.000211	0.000992	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL13—multiple sclerosis	0.000211	0.000992	CbGpPWpGaD
Dabigatran etexilate—Nausea—Prednisone—multiple sclerosis	0.000211	0.000519	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.00021	0.000988	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—multiple sclerosis	0.00021	0.000988	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Methotrexate—multiple sclerosis	0.00021	0.000516	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.000209	0.000982	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Methotrexate—multiple sclerosis	0.000203	0.000499	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—CYP24A1—multiple sclerosis	0.000201	0.000943	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP27B1—multiple sclerosis	0.000201	0.000943	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Methotrexate—multiple sclerosis	0.000196	0.000483	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—TAGAP—multiple sclerosis	0.000194	0.000909	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD80—multiple sclerosis	0.000193	0.000907	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—BCHE—multiple sclerosis	0.000192	0.000901	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL5—multiple sclerosis	0.00019	0.000891	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Methotrexate—multiple sclerosis	0.000189	0.000464	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—multiple sclerosis	0.000187	0.00046	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—multiple sclerosis	0.000187	0.00046	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—multiple sclerosis	0.000186	0.000457	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—GPC5—multiple sclerosis	0.000184	0.000862	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—BCHE—multiple sclerosis	0.000182	0.000854	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	0.00018	0.000844	CbGpPWpGaD
Dabigatran etexilate—Nausea—Methotrexate—multiple sclerosis	0.000176	0.000434	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000175	0.000824	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—multiple sclerosis	0.000174	0.000815	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000172	0.000807	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000172	0.000806	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	0.000171	0.000805	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCR5—multiple sclerosis	0.000171	0.000803	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—S1PR1—multiple sclerosis	0.000169	0.000795	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000167	0.000785	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GPC5—multiple sclerosis	0.000165	0.000773	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP24A1—multiple sclerosis	0.000163	0.000766	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP27B1—multiple sclerosis	0.000163	0.000766	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTGER4—multiple sclerosis	0.00016	0.000749	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000159	0.000749	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000155	0.00073	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000154	0.000724	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	0.000153	0.000717	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RRM1—multiple sclerosis	0.000152	0.000715	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2RA—multiple sclerosis	0.000151	0.000707	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL3—multiple sclerosis	0.00015	0.000707	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR2—multiple sclerosis	0.00015	0.000704	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPC5—multiple sclerosis	0.000149	0.000701	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTGER4—multiple sclerosis	0.000145	0.00068	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RGS1—multiple sclerosis	0.000144	0.000676	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—multiple sclerosis	0.000141	0.000663	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCR3—multiple sclerosis	0.00014	0.000657	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CNR1—multiple sclerosis	0.000138	0.00065	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GPR65—multiple sclerosis	0.000136	0.000641	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	0.000136	0.000639	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR2—multiple sclerosis	0.000136	0.000639	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—multiple sclerosis	0.000136	0.000637	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000134	0.00063	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000134	0.000629	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	0.000134	0.000628	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—POMC—multiple sclerosis	0.000134	0.000627	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	0.000131	0.000615	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL2—multiple sclerosis	0.000131	0.000614	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.00013	0.000612	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CNR1—multiple sclerosis	0.000126	0.00059	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL13—multiple sclerosis	0.000125	0.000586	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR1—multiple sclerosis	0.000125	0.000586	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000125	0.000585	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RRM1—multiple sclerosis	0.000124	0.000581	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—APOE—multiple sclerosis	0.000115	0.000542	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000115	0.000539	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL10—multiple sclerosis	0.000113	0.000531	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—multiple sclerosis	0.000109	0.000511	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCL5—multiple sclerosis	0.000107	0.000504	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SRM—multiple sclerosis	0.000106	0.000499	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	0.000106	0.000497	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000103	0.000484	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000103	0.000483	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—POMC—multiple sclerosis	9.91e-05	0.000466	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—multiple sclerosis	9.88e-05	0.000464	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL5—multiple sclerosis	9.73e-05	0.000457	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR5—multiple sclerosis	9.66e-05	0.000454	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	9.59e-05	0.000451	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2RA—multiple sclerosis	9.52e-05	0.000447	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—POMC—multiple sclerosis	9.39e-05	0.000441	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CCL2—multiple sclerosis	9.19e-05	0.000432	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	9.1e-05	0.000428	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—multiple sclerosis	9.04e-05	0.000425	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL3—multiple sclerosis	8.89e-05	0.000418	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—multiple sclerosis	8.83e-05	0.000415	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR5—multiple sclerosis	8.77e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—BCHE—multiple sclerosis	8.74e-05	0.00041	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2RA—multiple sclerosis	8.64e-05	0.000406	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTGER4—multiple sclerosis	8.56e-05	0.000402	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PGR—multiple sclerosis	8.43e-05	0.000396	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR3—multiple sclerosis	8.26e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.24e-05	0.000387	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD28—multiple sclerosis	8.19e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR2—multiple sclerosis	8.04e-05	0.000378	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—POMC—multiple sclerosis	7.55e-05	0.000355	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	7.51e-05	0.000353	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP24A1—multiple sclerosis	7.48e-05	0.000352	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP27B1—multiple sclerosis	7.48e-05	0.000352	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CNR1—multiple sclerosis	7.42e-05	0.000349	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BCHE—multiple sclerosis	7.1e-05	0.000334	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—multiple sclerosis	6.89e-05	0.000323	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—POMC—multiple sclerosis	6.85e-05	0.000322	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPC5—multiple sclerosis	6.84e-05	0.000322	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK1—multiple sclerosis	6.75e-05	0.000317	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL2—multiple sclerosis	6.71e-05	0.000315	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL10—multiple sclerosis	6.68e-05	0.000314	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TYK2—multiple sclerosis	6.09e-05	0.000286	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD86—multiple sclerosis	5.84e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL5—multiple sclerosis	5.75e-05	0.00027	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RRM1—multiple sclerosis	5.67e-05	0.000266	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—multiple sclerosis	5.58e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—multiple sclerosis	5.33e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—APOE—multiple sclerosis	5.26e-05	0.000247	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	5.23e-05	0.000246	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	5.22e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR5—multiple sclerosis	5.18e-05	0.000243	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	5.12e-05	0.00024	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2RA—multiple sclerosis	5.11e-05	0.00024	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—multiple sclerosis	5.07e-05	0.000238	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	4.87e-05	0.000229	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APOE—multiple sclerosis	4.71e-05	0.000221	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—POMC—multiple sclerosis	4.52e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—APOE—multiple sclerosis	4.27e-05	0.000201	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD80—multiple sclerosis	4.26e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—multiple sclerosis	4.12e-05	0.000193	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—POMC—multiple sclerosis	4.05e-05	0.00019	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL2—multiple sclerosis	3.96e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK1—multiple sclerosis	3.88e-05	0.000182	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—POMC—multiple sclerosis	3.67e-05	0.000172	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TYK2—multiple sclerosis	3.6e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—multiple sclerosis	3.35e-05	0.000157	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.28e-05	0.000154	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BCHE—multiple sclerosis	3.26e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—multiple sclerosis	2.99e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—multiple sclerosis	2.98e-05	0.00014	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—multiple sclerosis	2.83e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—multiple sclerosis	2.52e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—multiple sclerosis	2.34e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—multiple sclerosis	2.33e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK1—multiple sclerosis	2.29e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—APOE—multiple sclerosis	1.96e-05	9.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—multiple sclerosis	1.76e-05	8.26e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—POMC—multiple sclerosis	1.68e-05	7.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—multiple sclerosis	1.53e-05	7.21e-05	CbGpPWpGaD
